miR-1229 | ↑ | CRC diagnosis | 167 |
circ-KLDHC10 | ↑ | CRC diagnosis | 184 |
hsa_circ_0004771 | ↑ | CRC diagnosis | 185 |
hsa_circ_0005100 | ↑ | CRC diagnosis | 188 |
hsa_circ_0101802 | ↑ | CRC diagnosis | 189 |
circRHOBTB3 | ↑ | CRC diagnosis | 187 |
has_circ_0010522 | ↑ | CRC diagnosis | 183 |
hsa_circ_0067835 | ↑ | CRC diagnosis | 186 |
CPNE3 | ↑ | CRC diagnosis | 199 |
VEGF and CD133 | ↑ | Companion diagnosis receiving bevacizumab therapy | 196 |
lncRNA UCA1 | ↑ | Companion diagnosis receiving cetuximab therapy | 200 |
FZD10 | ↑ | Promoting EMT | 161 |
LINC00659 | ↑ | Promoting EMT | 141 |
miR-1229 | ↑ | Lymph node metastasis | 167 |
miR-128-3p | ↑ | Tumor stage | 201 |
miR-92a-3p | ↑ | Lung metastasis | 202 |
miR-106b-3p | ↑ | Lung metastasis | 160 |
HSPC111 | ↑ | Liver metastasis | 175 |
miR-25-3p | ↑ | Liver and lung metastasis | 168 |
circLONP2 | ↑ | Liver and lung metastasis | 203 |
miR-193a | ↓ | CRC progression | 204 |
let-7g | ↑ | CRC progression | 204 |
miR-221/222 | ↑ | CRC progression | 177 |
hsa_circ_0000338 | ↑ | Resistance to FOLFOX/5-FU | 205,206 |
lncRNA HOTTIP | ↑ | Resistance to mitomycin | 207 |
lncRNA H19 | ↑ | Resistance to oxaliplatin | 208 |
hsa_circ_0005963 | ↑ | Resistance to oxaliplatin | 209 |
lncRNA CCAL | ↑ | Resistance to oxaliplatin | 210 |
miR-46146 | ↑ | Resistance to oxaliplatin | 211 |
miR-208b | ↑ | Resistance to oxaliplatin | 212 |
p-STAT3 | ↑ | Resistance to 5-FU | 213 |
miR-21 | ↑ | Resistance to 5-FU | 214,215 |
miR-204-5p | ↑ | Enhancing sensitivity to 5-FU | 216 |
miR-92a-3p | ↑ | Resistance to oxaliplatin/5-FU | 202 |
Wnt | ↑ | Resistance to oxaliplatin/5-FU | 217 |
CPT1A siRNA | ↑ | Reverse oxaliplatin resistance | 218 |
Anti-miRNA-221 oligonucleotide | ↑ | Inhibit the proliferation and clonal formation of colon cancer cells | 219 |
Doxorubicin | ↑ | Drug delivery | 220–222 |